Mineralys Therapeutics announces positive results for hypertension treatment trials
From GlobeNewswire: 2025-03-10 07:00:00
Mineralys Therapeutics announced positive results from its pivotal trials of lorundrostat for uncontrolled or resistant hypertension. The Launch-HTN trial showed a significant reduction in systolic blood pressure at week 6 and week 12, while the Advance-HTN trial met its primary endpoint at week 12. Both trials demonstrated a favorable safety profile for lorundrostat.
The results from the Advance-HTN trial will be presented at the American College of Cardiology Scientific Sessions on March 29, 2025. Lorundrostat, an aldosterone synthase inhibitor, has shown potential to be a transformative therapy for millions of patients with uncontrolled hypertension. Mineralys plans to share additional data from these trials at upcoming medical conferences and in peer-reviewed publications.
The Launch-HTN trial enrolled participants who failed to achieve their blood pressure goal despite taking multiple antihypertensive medications. The trial demonstrated a significant reduction in systolic blood pressure with lorundrostat treatment, supporting its efficacy in lowering blood pressure in diverse patient populations. The favorable results highlight the potential of lorundrostat as a treatment option for patients with high blood pressure.
The Advance-HTN trial evaluated lorundrostat as an add-on therapy for uncontrolled or resistant hypertension in adult subjects. The trial achieved its primary endpoint, showing a significant reduction in systolic blood pressure at week 12. The safety and tolerability of lorundrostat in this trial were consistent with findings from the Launch-HTN trial.
Mineralys Therapeutics is focused on developing medicines to target hypertension, chronic kidney disease, obstructive sleep apnea, and other conditions driven by dysregulated aldosterone. Lorundrostat, a highly selective aldosterone synthase inhibitor, has shown promising results in clinical trials for uncontrolled and resistant hypertension. The company is dedicated to advancing innovative therapies for cardiorenal conditions affected by dysregulated aldosterone.
Read more at GlobeNewswire: Mineralys Therapeutics Announces Positive Topline Results